Research: KPMG H1 2026 M&A Trends in Healthcare · Published September 8, 2026

Healthcare M&A Value Fell 79%. KPMG Says Buyers Still Want RCM Infrastructure.

Healthcare dealmaking slowed sharply during the first half of 2026. But the more useful signal in KPMG's latest sector report is what buyers continued to pursue: connected healthcare technology, operational infrastructure, and assets that can improve real financial performance. Revenue cycle management is explicitly part of that investment thesis.

KPMG's H1 2026 healthcare M&A report, released September 8, records 361 U.S. healthcare transactions with $8.6 billion in disclosed deal value during January through June 2026. Deal count declined 12.6% from the first half of 2025; disclosed value dropped 79.2%.

A headline reading of those figures would suggest healthcare M&A nearly collapsed. KPMG cautions that the comparison is heavily affected by large transactions in prior periods, including megadeals. A smaller disclosed value total does not mean buyers abandoned healthcare assets.

The more instructive figure is underneath the aggregate: healthcare IT and digital health accounted for 121 transactions and $5.0 billion of disclosed deal value, the largest healthcare subsector by disclosed value. KPMG specifically cites persistent acquisition interest in revenue cycle management, payer enablement, and health information platforms.

The Market Isn't Closed. The Buyer Has Changed.

Strategic acquirers completed or announced 242 transactions in KPMG's H1 dataset, accounting for about 67% of deal volume and approximately $8.0 billion of disclosed value. Private equity activity was softer: sponsor deal volume fell 17.5% year over year.

That shift changes what a good healthcare technology asset needs to prove.

A financial sponsor can underwrite margin expansion, recurring revenue, and a future exit. A strategic buyer often requires a second answer: how does this company make the acquirer's existing operating model more valuable?

For RCM vendors, that is not necessarily about a better claim dashboard. It might mean automation that reduces denials in an existing customer base, proprietary payment or payer-policy data, embedded eligibility and authorization workflows, or technology that increases a broader platform's collections and customer retention.

The most attractive acquisition target may be a small business with a defensible position in the workflow—not simply a larger company with the most revenue.

Healthcare IT Was the Largest Subsector by Disclosed Deal Value

KPMG's $5.0 billion healthcare IT/digital health figure includes enterprise imaging, virtual care and other technology businesses; it is not $5.0 billion of RCM acquisitions. That distinction matters.

The report identifies several reasons technology remained attractive despite the overall slowdown: interoperable platforms, administrative productivity, better clinical throughput, cloud architecture, and operational efficiency.

One example is GE HealthCare's $2.3 billion acquisition of Intelerad, which KPMG identifies as H1's largest healthcare deal. Another is Inventurus Knowledge Solutions' approximately $570 million acquisition of TruBridge, listed among the period's notable transactions.

The latter is especially relevant for revenue cycle. IKS combines technology-enabled healthcare operations and revenue cycle services, while TruBridge brings provider-facing technology and related RCM capabilities. The industrial logic is not simply more software or more billing labor. It is creating a broader financial operations platform with existing customers, workflows, and opportunities to execute.

The New Due Diligence Test: Does the Technology Work in Production?

KPMG makes a useful distinction between product functionality and enterprise readiness. Acquirers need to evaluate implementation complexity, data architecture, integration cost, cybersecurity, and customer retention by use case—not merely whether a vendor claims to have AI or cloud features.

That warning is particularly important in revenue cycle, where implementations can involve dozens of payer connections, EHR integrations, historical denials, practice-specific charge rules, and payer-by-payer reimbursement logic.

An agent that drafts appeals is easy to demonstrate. An agent that follows each payer's rules, navigates required evidence, resolves exceptions, and measurably improves collections over time is harder to reproduce.

The same applies to coding, authorization, medical necessity and underpayment detection. Differentiation comes from accuracy, operational controls, integrated data and financial results—not AI branding.

RCM Diligence Starts With Reimbursement, Not Revenue Growth

One of the report's strongest investment recommendations is to examine reimbursement exposure earlier in diligence. KPMG points buyers toward payer mix, reimbursement concentration, policy sensitivity, and earnings sustainability.

For an RCM acquisition, that lens should apply in two directions.

First, the services business: What specialties and payers drive the client's collections? Are changes in reimbursement, staffing, claim volumes, or payer contract terms affecting net revenue? How much of the company's margin depends on a single customer or operating model?

Second, the technology business: Does the platform's claimed uplift show up as paid dollars rather than flagged opportunities? Does it perform against real payer policies? What proportion of work can be completed without costly manual exception handling?

Those questions are more important than ever in an environment where both payers and providers are investing in automation.

A Smaller Specialist Can Have a Bigger Strategic Role

KPMG describes selective interest in healthcare services with differentiated specialty knowledge, durable referral relationships, and disciplined operations. It also cautions that fragmented services businesses can take longer to integrate than their financial projections assume.

That suggests a potential opportunity for smaller, specialized RCM firms that have deep competence in areas such as specialty authorizations, complex claims, dental reimbursement, provider enrollment, or underpayment recovery.

But specialization alone is not the advantage. The acquirer needs evidence the knowledge can be scaled beyond a handful of employees without losing quality.

Useful proof includes documented playbooks, reliable payer and procedure intelligence, standardized quality assurance, customer retention, a clean compliance record, and repeatable financial improvement.

In other words, the most interesting RCM roll-up strategy may be to acquire specialized operational intelligence and build a shared execution infrastructure around it—rather than buying generic billing volumes and assuming automation will solve the integration later.

What KPMG's H1 Data Means for H2 Deals

This report covers transactions announced or closed during the first half of 2026. It should not be confused with a Q3 market update or treated as a live count of the latest October transactions.

Its predictions, however, are relevant to the more recent healthcare funding and acquisition news. KPMG expects strategic acquirers to remain comparatively active and points to continued interest in workflow automation, AI-supported productivity, outpatient care and specialized healthcare services.

Consider the common thread across recent RCAI reporting: Suki's $90 million financing centers on embedded clinical AI agents; McKesson's announced Option Care transaction points toward more integrated specialty operations; and Rock Health's Q3 analysis argues that deploying and integrating technology is becoming a critical differentiator.

Those October developments were not included in KPMG's H1 dataset. They illustrate why its underlying thesis—the movement from scale and features toward operational value—remains relevant.

Five Questions RCM Investors Should Ask

• What is the demonstrated financial outcome? Measure cash collected, denials prevented, cycle time, and cost to collect—not only AI usage or opportunities identified.
• Who owns the data advantage? Examine payer responses, adjudicated claims, reimbursement benchmarks, workflow history, and the rights to use and improve that data.
• Can the platform survive integration? Test EHR, clearinghouse, payer and client-specific interoperability before making acquisition assumptions.
• Where is the reimbursement risk? Underwrite payer concentration, fee-schedule changes, policy sensitivity, and client economics alongside reported EBITDA.
• Is the capability truly repeatable? Determine whether performance depends on a handful of exceptional operators or a system that can scale.

RCAI Take

KPMG's headline is a weaker healthcare M&A market. Its more meaningful finding is a tougher market for undifferentiated assets.

Healthcare IT remained the largest subsector by disclosed deal value, and KPMG specifically identified RCM and payer enablement among areas of buyer interest. That does not guarantee a premium valuation for every AI-enabled RCM company. It raises the bar for what buyers expect.

Investors will keep looking for platforms that can convert specialized knowledge into scalable operating advantages: better reimbursement intelligence, fewer preventable denials, more automated resolution, and durable customer economics.

The buyer is no longer asking only what the software does. The buyer is asking what financial work the company can reliably eliminate, improve, or control.

Source: KPMG, M&A Trends in Healthcare — H1 2026 (September 8, 2026); KPMG's accompanying healthcare M&A analysis. Deal counts, transaction values and KPMG viewpoints are attributed to that H1 report. RCM diligence and investment implications are independent RevCycleAI analysis. The report's disclosed-value totals are not exhaustive of all transaction values.